Skip to main content
. 2009 Jul 13;119(8):2257–2270. doi: 10.1172/JCI35738

Figure 2. Systemic administration of VEGF and LPS results in organ-specific increases in DSCR1s promoter activity.

Figure 2

(A and B) Comparative whole-mount lacZ stains of brain (A) and heart (B) taken from untreated (control), LPS-treated, or VEGF-treated mice. (C) Whole-mount lacZ stains of thigh skeletal muscle from Flt-1-lacZ-Hprt or DSCR-1s-lacZ-Hprt mice treated without (left panel) or with LPS (right panel).